Stephanie E. Siegmund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stephanie E. Siegmund has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Michelle S. Hirsch
Brigham and Women’s Hospital, Harvard Medical School
10 shared publications - Jason Laurence Hornick
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
9 shared publications - Bradley Alexander McGregor
Dana-Farber Cancer Institute 1 Lank Center for Genitourinary Oncology Boston, Massachusetts
8 shared publications - Charlene Mantia
Dana-Farber Cancer Institute 1 Lank Center for Genitourinary Oncology Boston, Massachusetts
8 shared publications - Clara Steiner
Dana-Farber Cancer Institute, Boston, MA 02215, USA
8 shared publications - David James Papke
Department of Pathology, Brigham and Women’s Hospital, and Harvard Medical School, Boston, USA
8 shared publications
Latest Publications
- 14 October 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
MR Imaging and Radiomics Features for Predicting Variant Histology of Bladder Cancer: A Single Centre Retrospective Analysis
Introduction: Compare MRI features of bladder variant histology (VH) and pure urothelial carcinoma (UC) and determine if MRI radiomics features can predict VH. Methods: In this retrospective study, cystectomy pathology database search yielded 37 patients with tumours with more than 50% VH and preoperative MRI's. Cystectomy database search yielded 38 consecutive patients with pure UC and preoperative MRI's. Three radiologists characterized MRI T2, diffusion‐weighted, apparent diffusion coefficient (ADC) maps and postcontrast features of bladder tumours. Inter‐reader agreement was assessed using Gwet's agreement and intra‐class coefficients. Another radiologist segmented bladder tumours and adjacent perivesical fat on T2‐weighted and ADC images using radiomics software. Least absolute shrinkage and selection operator (LASSO) was used to determine radiomics features that distinguished VH from UC. Fifty datasets were prepared using multiple imputation approach, and variables were normalized for LASSO variable selection. Results: Patients with VH (mean age = 68, 54 (72%) men) included squamous cell ( n = 17), sarcomatoid ( n = 6), plasmacytoid ( n = 6), adenocarcinoma ( n = 4) and small cell ( n = 4) variants. Inter‐reader agreement was similar for VH and UC ( p > 0.44). All readers characterized all squamous cell carcinoma as T2 intermediate. For two of three readers, 92%–100% of hypoenhancing tumours were VH at pathology whereas 74%–78% of hyperenhancing masses were UC ( p = 0.001). Combination of 11 selected radiomics features had AUC of 0.98 for training and 0.95 for validation data for prediction of VH. Conclusion: Squamous cell carcinoma was T2 intermediate, and VH was more likely to hypoenhance compared to UC. Our radiomic model had excellent performance for predicting VH.
- 14 October 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
MR Imaging and Radiomics Features for Predicting Variant Histology of Bladder Cancer: A Single Centre Retrospective Analysis
Introduction: Compare MRI features of bladder variant histology (VH) and pure urothelial carcinoma (UC) and determine if MRI radiomics features can predict VH. Methods: In this retrospective study, cystectomy pathology database search yielded 37 patients with tumours with more than 50% VH and preoperative MRI's. Cystectomy database search yielded 38 consecutive patients with pure UC and preoperative MRI's. Three radiologists characterized MRI T2, diffusion‐weighted, apparent diffusion coefficient (ADC) maps and postcontrast features of bladder tumours. Inter‐reader agreement was assessed using Gwet's agreement and intra‐class coefficients. Another radiologist segmented bladder tumours and adjacent perivesical fat on T2‐weighted and ADC images using radiomics software. Least absolute shrinkage and selection operator (LASSO) was used to determine radiomics features that distinguished VH from UC. Fifty datasets were prepared using multiple imputation approach, and variables were normalized for LASSO variable selection. Results: Patients with VH (mean age = 68, 54 (72%) men) included squamous cell ( n = 17), sarcomatoid ( n = 6), plasmacytoid ( n = 6), adenocarcinoma ( n = 4) and small cell ( n = 4) variants. Inter‐reader agreement was similar for VH and UC ( p > 0.44). All readers characterized all squamous cell carcinoma as T2 intermediate. For two of three readers, 92%–100% of hypoenhancing tumours were VH at pathology whereas 74%–78% of hyperenhancing masses were UC ( p = 0.001). Combination of 11 selected radiomics features had AUC of 0.98 for training and 0.95 for validation data for prediction of VH. Conclusion: Squamous cell carcinoma was T2 intermediate, and VH was more likely to hypoenhance compared to UC. Our radiomic model had excellent performance for predicting VH.
- 6 May 2026
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 43 (3) , 151011
Recent advances in genetic predisposition to primary testicular tumors
- 6 May 2026
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 43 (3) , 151011
Recent advances in genetic predisposition to primary testicular tumors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S3. Kaplan–Meier curves for (A) overall survival (OS) and (B)progression-free survival (PFS) stratified by treatment group (immune checkpoint inhibitor (IO), tyrosine kinase inhibitor (TKI), and IO + TKI). Median survival times with 95% confidence intervals (CI) and log-rank p-values are shown within each panel. Number-at-risk tables are displayed below the curves.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S3. Kaplan–Meier curves for (A) overall survival (OS) and (B)progression-free survival (PFS) stratified by treatment group (immune checkpoint inhibitor (IO), tyrosine kinase inhibitor (TKI), and IO + TKI). Median survival times with 95% confidence intervals (CI) and log-rank p-values are shown within each panel. Number-at-risk tables are displayed below the curves.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S1. Cohort Flow Diagram Flowchart summarizing the distribution of the 33 patients by disease stage at presentation and subsequent treatment. Sixteen patients were metastatic at diagnosis, and ten additional patients developed metastases during follow-up. Among metastatic cases, 23 received systemic therapy (Biphasic Hyalinizing Psammomatous [BHP] n = 13; non-BHP n = 10), while 3 received no systemic treatment (all BHP). Locoregional patients who did not develop metastases were treated with BHP (n = 6) or non-BHP (n = 1). Dashed arrows indicate progression to metastatic disease.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S1. Cohort Flow Diagram Flowchart summarizing the distribution of the 33 patients by disease stage at presentation and subsequent treatment. Sixteen patients were metastatic at diagnosis, and ten additional patients developed metastases during follow-up. Among metastatic cases, 23 received systemic therapy (Biphasic Hyalinizing Psammomatous [BHP] n = 13; non-BHP n = 10), while 3 received no systemic treatment (all BHP). Locoregional patients who did not develop metastases were treated with BHP (n = 6) or non-BHP (n = 1). Dashed arrows indicate progression to metastatic disease.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Purpose:In renal cell carcinoma (RCC), loss of the NF2 tumor suppressor gene encoding the merlin protein is associated with aggressive clinical behavior. However, data about the clinical course and additional molecular features in the context of contemporary systemic therapies remain limited.Experimental Design:Clinical outcomes were evaluated in patients with RCC exhibiting merlin loss by IHC in one academic cohort. Integrative genomic analyses were performed, including targeted DNA sequencing via the institutional OncoPanel assay and RNA sequencing data from The Cancer Genome Atlas (TCGA).Results:In the institutional cohort (n = 33), most patients had biphasic hyalinizing psammomatous RCC (66.6%) and metastatic disease (78.8%). Among 23 patients receiving systemic therapy, those treated with non-immunotherapy (IO)–based regimens (n = 5) had numerically longer overall survival (24.5 vs. 16.5 months, P = 0.2) and progression-free survival (9.8 vs. 5 months, P = 0.5) compared with IO-based therapies (n = 18) though differences were not statistically significant. Genomic analysis (n = 17) revealed frequent truncating mutations of NF2 (82.3%) and recurrent alterations in chromatin remodeling and DNA damage–response signaling genes with prominent deletions in tumor suppressor genes such as CDKN2A/B. Transcriptomic profiling of NF2-inactivated tumors from TCGA (n = 13) demonstrated enrichment of cellular proliferation and concurrent suppression of metabolic and immune pathways, suggesting an aggressive phenotype compared with clear-cell RCC without NF2 inactivation (n = 529).Conclusions:Biallelic NF2 inactivation and merlin protein deficiency drive an aggressive RCC phenotype marked by immune dysfunction, high proliferation, and frequent cell cycle and DNA damage–response signaling alterations. Limited treatment response to IO highlights the need for molecularly tailored therapies.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Purpose:In renal cell carcinoma (RCC), loss of the NF2 tumor suppressor gene encoding the merlin protein is associated with aggressive clinical behavior. However, data about the clinical course and additional molecular features in the context of contemporary systemic therapies remain limited.Experimental Design:Clinical outcomes were evaluated in patients with RCC exhibiting merlin loss by IHC in one academic cohort. Integrative genomic analyses were performed, including targeted DNA sequencing via the institutional OncoPanel assay and RNA sequencing data from The Cancer Genome Atlas (TCGA).Results:In the institutional cohort (n = 33), most patients had biphasic hyalinizing psammomatous RCC (66.6%) and metastatic disease (78.8%). Among 23 patients receiving systemic therapy, those treated with non-immunotherapy (IO)–based regimens (n = 5) had numerically longer overall survival (24.5 vs. 16.5 months, P = 0.2) and progression-free survival (9.8 vs. 5 months, P = 0.5) compared with IO-based therapies (n = 18) though differences were not statistically significant. Genomic analysis (n = 17) revealed frequent truncating mutations of NF2 (82.3%) and recurrent alterations in chromatin remodeling and DNA damage–response signaling genes with prominent deletions in tumor suppressor genes such as CDKN2A/B. Transcriptomic profiling of NF2-inactivated tumors from TCGA (n = 13) demonstrated enrichment of cellular proliferation and concurrent suppression of metabolic and immune pathways, suggesting an aggressive phenotype compared with clear-cell RCC without NF2 inactivation (n = 529).Conclusions:Biallelic NF2 inactivation and merlin protein deficiency drive an aggressive RCC phenotype marked by immune dysfunction, high proliferation, and frequent cell cycle and DNA damage–response signaling alterations. Limited treatment response to IO highlights the need for molecularly tailored therapies.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S2. Systemic Therapy Sequences Across Treatment Lines This Sankey diagram illustrates the distribution and transitions of systemic therapies across treatment lines in the cohort. The first column represents treatments received in the first-line setting, followed by subsequent columns showing second-, third-, fourth-, and fifth-line therapies. Each colored flow corresponds to a specific drug or drug combination, with stream widths proportional to the number of patients receiving that regimen. The diagram highlights the heterogeneity of treatment patterns, sequencing, and the diversity of regimens used over the course of therapy.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S2. Systemic Therapy Sequences Across Treatment Lines This Sankey diagram illustrates the distribution and transitions of systemic therapies across treatment lines in the cohort. The first column represents treatments received in the first-line setting, followed by subsequent columns showing second-, third-, fourth-, and fifth-line therapies. Each colored flow corresponds to a specific drug or drug combination, with stream widths proportional to the number of patients receiving that regimen. The diagram highlights the heterogeneity of treatment patterns, sequencing, and the diversity of regimens used over the course of therapy.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S4. The Cancer Genome Atlas (TCGA) Mutation Landscape in NF2-Altered Renal Cell Carcinoma
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Supplementary Figure S4. The Cancer Genome Atlas (TCGA) Mutation Landscape in NF2-Altered Renal Cell Carcinoma
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Representativeness of Study Participants
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Representativeness of Study Participants
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
DESeq2 differential expression results
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
DESeq2 differential expression results
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1169-1179
Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Purpose: In renal cell carcinoma (RCC), loss of the NF2 tumor suppressor gene encoding the merlin protein is associated with aggressive clinical behavior. However, data about the clinical course and additional molecular features in the context of contemporary systemic therapies remain limited. Experimental Design: Clinical outcomes were evaluated in patients with RCC exhibiting merlin loss by IHC in one academic cohort. Integrative genomic analyses were performed, including targeted DNA sequencing via the institutional OncoPanel assay and RNA sequencing data from The Cancer Genome Atlas (TCGA). Results: In the institutional cohort (n = 33), most patients had biphasic hyalinizing psammomatous RCC (66.6%) and metastatic disease (78.8%). Among 23 patients receiving systemic therapy, those treated with non-immunotherapy (IO)–based regimens (n = 5) had numerically longer overall survival (24.5 vs. 16.5 months, P = 0.2) and progression-free survival (9.8 vs. 5 months, P = 0.5) compared with IO-based therapies (n = 18) though differences were not statistically significant. Genomic analysis (n = 17) revealed frequent truncating mutations of NF2 (82.3%) and recurrent alterations in chromatin remodeling and DNA damage–response signaling genes with prominent deletions in tumor suppressor genes such as CDKN2A/B. Transcriptomic profiling of NF2-inactivated tumors from TCGA (n = 13) demonstrated enrichment of cellular proliferation and concurrent suppression of metabolic and immune pathways, suggesting an aggressive phenotype compared with clear-cell RCC without NF2 inactivation (n = 529). Conclusions: Biallelic NF2 inactivation and merlin protein deficiency drive an aggressive RCC phenotype marked by immune dysfunction, high proliferation, and frequent cell cycle and DNA damage–response signaling alterations. Limited treatment response to IO highlights the need for molecularly tailored therapies.
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1169-1179
Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Purpose: In renal cell carcinoma (RCC), loss of the NF2 tumor suppressor gene encoding the merlin protein is associated with aggressive clinical behavior. However, data about the clinical course and additional molecular features in the context of contemporary systemic therapies remain limited. Experimental Design: Clinical outcomes were evaluated in patients with RCC exhibiting merlin loss by IHC in one academic cohort. Integrative genomic analyses were performed, including targeted DNA sequencing via the institutional OncoPanel assay and RNA sequencing data from The Cancer Genome Atlas (TCGA). Results: In the institutional cohort (n = 33), most patients had biphasic hyalinizing psammomatous RCC (66.6%) and metastatic disease (78.8%). Among 23 patients receiving systemic therapy, those treated with non-immunotherapy (IO)–based regimens (n = 5) had numerically longer overall survival (24.5 vs. 16.5 months, P = 0.2) and progression-free survival (9.8 vs. 5 months, P = 0.5) compared with IO-based therapies (n = 18) though differences were not statistically significant. Genomic analysis (n = 17) revealed frequent truncating mutations of NF2 (82.3%) and recurrent alterations in chromatin remodeling and DNA damage–response signaling genes with prominent deletions in tumor suppressor genes such as CDKN2A/B. Transcriptomic profiling of NF2-inactivated tumors from TCGA (n = 13) demonstrated enrichment of cellular proliferation and concurrent suppression of metabolic and immune pathways, suggesting an aggressive phenotype compared with clear-cell RCC without NF2 inactivation (n = 529). Conclusions: Biallelic NF2 inactivation and merlin protein deficiency drive an aggressive RCC phenotype marked by immune dysfunction, high proliferation, and frequent cell cycle and DNA damage–response signaling alterations. Limited treatment response to IO highlights the need for molecularly tailored therapies.